Misha Dolmatov | Searcharxiv

arXiv2026

Semi- and non-parametric approaches to individualized treatment regimes in the presence of causal mediation

Individualized treatment rules (ITRs) map an individual patient's characteristics to their recommended treatment value. Typically, the optimal ITR is defined as the rule which maximizes a mean counterfactual outcome; the resulting ITR maximizes the effect of treatment along all causal pathways to the outcome, including indirect pathways through mediating variables. Although maximizing the total effect is often sufficient, explicitly incorporating causal mediation in an ITR analysis has several potential benefits such as enhanced interpretability, and additional flexibility in targeting specific causal pathways. For this purpose, we introduce novel Bayesian semiparametric and nonparametric estimators for conditional mediation effects in the presence of multiple mediators and show how they can be used to estimate optimal ITRs. We demonstrate the proposed methodology via an application to optimal kidney allocation with hepatitis C positive donors.

stat.ME↗

arXiv2025

Individualized treatment regimens under correlated data with multiple outcomes

Precision medicine involves developing individualized treatment regimes (ITRs) which allow for treatment decisions to be tailored to patient characteristics. Naturally, the identification of the optimal regime, that is, the rule which maximizes patient outcomes, is of interest. Several procedures for estimating optimal ITRs from observational data have been proposed; however, relatively few methods exist for estimating optimal ITRs in the presence of competing risks. Previous approaches either target one particular cause of failure, or rely on singly-robust estimators. We propose a novel doubly-robust regression-based method for estimating optimal ITRs which accounts for the uncertainty related to the unobserved cause of failure by averaging over all possible causes, or targeting the most likely cause. Our approach is straightforward to implement, and we demonstrate an extension to incorporate clustering, motivated by the question of for whom kidney transplantation with hepatitis C virus (HCV)-positive donors is safe, using data from the Organ Procurement and Transplantation Network. Our analysis suggests that a large portion of HCV-negative kidney recipients would see their overall survival unchanged if they were instead provided a kidney from an HCV-positive donor. The estimated treatment rules could be used to provide more efficient allocation of HCV-positive kidneys, increasing the donor pool.

stat.ME↗